Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.15 -0.19 (-1.10%)

Official Closing Price Updated: 6:30 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

BLCO Stock Still 16% Below IPO — Is Silver Point’s $38.7 Million Bet a Turning Point? ↗

December 03, 2025

One fund just made a bold move on an eye-care giant—here’s why it may signal a deeper shift in the company’s long-term trajectory.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Why Bausch + Lomb (BLCO) Stock Is Up Today

December 02, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 4.2% in the morning session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal Weight.". The investment bank...

Via StockStory

Topics Economy Initial Public Offering

3 Small-Cap Stocks with Warning Signs

December 01, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

3 Cash-Burning Stocks We Approach with Caution

November 23, 2025

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.

Via StockStory

Option Care Health, DaVita, Revvity, West Pharmaceutical Services, and Bausch + Lomb Shares Skyrocket, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy

Bausch + Lomb to Participate in Citi Global Healthcare Conference

November 18, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

November 13, 2025

From Bausch + Lomb Corporation

Via Business Wire

Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Via StockStory

Topics Artificial Intelligence Stocks

Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program

November 10, 2025

From Bausch + Lomb Corporation

Via Business Wire

Medical Devices & Supplies - Specialty Stocks Q3 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers

November 10, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - specialty stocks fared in Q3,...

Via StockStory

5 Revealing Analyst Questions From Bausch + Lomb’s Q3 Earnings Call

November 05, 2025

Bausch + Lomb’s third quarter saw a positive market response, as the company posted growth across all major segments and met Wall Street’s revenue expectations. Management highlighted that strong...

Via StockStory

Topics Earnings

Bausch + Lomb to Hold Investor Day on Nov. 13

November 03, 2025

From Bausch + Lomb Corporation

Via Business Wire

BLCO Q3 Deep Dive: Pharmaceuticals and Pipeline Drive Growth, Margin Initiatives Take Shape

October 30, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) met Wall Streets revenue expectations in Q3 CY2025, with sales up 7.1% year on year to $1.28 billion. The company’s outlook for the full year was close to...

Via StockStory

Topics World Trade

Bausch + Lomb Corp (NYSE:BLCO) Q3 2025 Earnings: EPS Beat and Reaffirmed Guidance Drive Shares Higher ↗

October 29, 2025

Bausch + Lomb (BLCO) Q3 2025 earnings beat EPS estimates by 11.9% and reaffirmed its full-year outlook, driving shares up in pre-market trading.

Via Chartmill

Topics Earnings

Bausch + Lomb (NYSE:BLCO) Reports Q3 In Line With Expectations, Stock Soars

October 29, 2025

Via StockStory

Bausch + Lomb Announces Third-Quarter 2025 Results

October 29, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb (BLCO) To Report Earnings Tomorrow: Here Is What To Expect

October 27, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know

October 20, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 3.1% in the morning session after reports revealed an activist investor, Jana Partners, took a stake in competitor Cooper Companies and was...

Via StockStory

Topics Initial Public Offering World Trade

Activist Investor Turns Up Heat On Cooper, Urges Bausch + Lomb Merger To Boost Returns: Report ↗

October 19, 2025

Jana Partners is urging Cooper to improve capital use and returns, saying its contact-lens and women’s health units lack strategic fit and drag on performance.

Via Stocktwits

3 Stocks Under $50 We Steer Clear Of

October 17, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

Topics Economy Supply Chain

3 Unpopular Stocks Walking a Fine Line

October 03, 2025

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

September 29, 2025

From Bausch + Lomb Corporation

Via Business Wire

1 Small-Cap Stock to Keep an Eye On and 2 That Underwhelm

September 26, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know

September 25, 2025

A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential...

Via StockStory

Topics Economy Government World Trade

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

September 11, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

September 09, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb (BLCO) Stock Trades Up, Here Is Why

September 08, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 2.9% in the afternoon session after the company announced the U.S. launch of its ASANA gas permeable (GP) lenses. This new product line offers...

Via StockStory

Topics Economy Initial Public Offering Stocks

Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States

September 08, 2025

From Bausch + Lomb Corporation

Via Business Wire

3 Healthcare Stocks Walking a Fine Line

September 05, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...

Via StockStory

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.